AUG 15, 2026 · JOURNAL ARTICLE
The Prognostic Significance of the NOLUS Score in Patients with Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor Therapy
Acta Medica Alanya
Single-center retrospective study of 76 patients testing a novel biomarker score (NOLUS) that failed to show prognostic significance; generates null findings on the primary hypothesis and real-world comparative data but lacks the rigor and external validation needed for clinical recommendation.
Reported
Sample size76
Median follow-up38.4 months
Median PFS (low-NOLUS)36.6 months